LifeVantage Corporation enters the week in a rare position: the stock is up 29% over the past month yet short sellers are still sitting on one of the heaviest positions in the entire market. That contradiction — squeezed longs rallying hard into an immovable short base — is the defining tension right now.
The lending market tells an unambiguous story of extreme pressure. Short interest runs at 42% of the free float, a figure that has barely budged despite the stock's sharp recovery — it edged down only fractionally over the past week. Far more telling is the cost to borrow: 116% annualised as of May 5, up 88% over the past week alone and up roughly 260% over the past month. A month ago borrowing LFVN cost around 32%; today it costs more than three times that. Availability has tightened to near zero — the lending pool is almost entirely spoken out, having run at or above 97% utilisation for the past six weeks with multiple days at the absolute ceiling. The ORTEX short score has climbed to 98.1 out of 100, among the highest in the US market and rising steadily. Days to cover run at 21, meaning at current trading volumes it would take three full weeks of buying to clear the short book. This is about as tight a borrow situation as a stock can be in.
Options traders are reading the tape very differently from short sellers. The put/call ratio has collapsed to just 0.24 — well below the 20-day average of 0.50 — sitting near its 52-week low. That marks a decisive shift from early April, when the PCR sat above 0.80 and options positioning leaned heavily defensive. Over the past three weeks, hedgers have largely unwound. Call buying now dominates. The divergence between an extreme short position and a call-dominated options market is sharp and unusual.
The analyst picture is thin and somewhat dated. The sole active price target comes from Freedom Broker, which maintained a Buy in February but lowered its target to $8 from $11. That $8 target still sits 46% above the current price of $5.49, consistent with the screening data showing a 45.7% analyst return potential. However, the most recent rating action is 77 days old, and prior targets from Craig-Hallum ($35) and Lake Street ($26) date back to late 2024 and early 2025 — those figures are far too stale to carry weight at the current price level. The institutional base is notable: Capital Management Corporation holds roughly 19% of shares, with Renaissance Technologies and BlackRock among the other top holders. The top five institutions collectively own nearly 45% of the company.
Insider activity adds another layer to the story. The 90-day net balance is positive at roughly 65,000 shares and $320,000 in value — driven primarily by independent director Dayton Judd, who bought around 33,000 shares across three separate purchases in late February and early March at prices between $4.53 and $4.63. Two other independent directors also added shares in that window. On the other side, the CEO and CFO each sold token amounts on April 1 at $4.20 — routine in size and at prices below the current level. The director cluster-buying into the weakness earlier this year is the more meaningful signal.
The company reported its most recent quarterly results on May 6, with no next event date currently set. The prior print in February saw a 14% one-day decline and a 5% loss over the following five days. With a market cap of approximately $70 million and an EV near $43 million, the stock is micro-cap by any measure — thin and volatile. What to watch from here is whether the cost-to-borrow escalation continues to deter new short entry, or whether the heavy existing short base starts to cover as the stock holds its recent gains. The gap between a near-maxed borrow market and an options market showing little hedging demand is the clearest pressure point to track.
See the live data behind this article on ORTEX.
Open LFVN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
